CYTX vs. ACHV, RIGL, RGLS, SGMO, VSTM, CRIS, FBIO, BOLT, SABS, and MTEM
Should you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Sangamo Therapeutics (SGMO), Verastem (VSTM), Curis (CRIS), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), and Molecular Templates (MTEM). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences (NASDAQ:ACHV) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 2.6% of Cytori Therapeutics shares are owned by institutional investors. 2.0% of Achieve Life Sciences shares are owned by insiders. Comparatively, 0.7% of Cytori Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Achieve Life Sciences has a net margin of 0.00% compared to Achieve Life Sciences' net margin of -242.60%. Cytori Therapeutics' return on equity of -176.97% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Cytori Therapeutics received 112 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. Likewise, 73.67% of users gave Cytori Therapeutics an outperform vote while only 70.21% of users gave Achieve Life Sciences an outperform vote.
Achieve Life Sciences presently has a consensus price target of $14.00, suggesting a potential upside of 168.20%. Given Cytori Therapeutics' higher probable upside, research analysts clearly believe Achieve Life Sciences is more favorable than Cytori Therapeutics.
Cytori Therapeutics has higher revenue and earnings than Achieve Life Sciences.
In the previous week, Achieve Life Sciences had 3 more articles in the media than Cytori Therapeutics. MarketBeat recorded 3 mentions for Achieve Life Sciences and 0 mentions for Cytori Therapeutics. Cytori Therapeutics' average media sentiment score of 0.86 beat Achieve Life Sciences' score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media.
Summary
Achieve Life Sciences beats Cytori Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Cytori Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytori Therapeutics Competitors List
Related Companies and Tools
